地塞米松联合康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床研究

Clinical study of Dexamethasone combined with Conbercept in the treatment of macular edema secondary to branch retinal vein occlusion

目的探讨地塞米松联合康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的临床疗效。方法选取2020年3月至2023年3月新余市人民医院收治的80例BRVO继发ME患者作为研究对象,采用随机信封法分为对照组(n=40)和研究组(n=40)。对照组接受玻璃体腔注射康柏西普治疗,在此基础上研究组加用玻璃体腔注射地塞米松。比较两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT),药物注射次数,药物不良反应发生率。结果两组患者治疗后1、3、6个月的CMT低于本组治疗前,差异有统计学意义(P<0.05)。两组患者治疗后1、3、6个月的BCVA低于本组治疗前,差异有统计学意义(P<0.05)。研究组平均注射次数低于对照组,差异有统计学意义(P<0.05)。两组药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论地塞米松与康柏西普联用是治疗BRVO继发ME有效且安全的方案,能有效减少黄斑水肿,促进视力恢复,且药物追加注射次数少。

Objective To investigate the clinical efficacy of Dexamethasone combined with Conbercept in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO).Methods A total of 80 patients with ME secondary BRVO admitted to Xinyu People's Hospital from March 2020 to March 2023 were selected as the study objects,and they were divided into control group(n=40)and study group(n=40)by random envelope method.The control group received in-travitreal injection of Conbercept,and the study group received intravitreal injection of Dexamethasone.The best corrected visual acuity(BCVA),central macular thickness(CMT),the number of drug injections and the incidence of adverse drug reactions were compared between the two groups before and after treatment.Results The CMT of two groups at 1,3 and 6 months after treatment was lower than that before treatment,and the difference was statistically significant(P<0.05).The BCVA of two groups at 1,3 and 6 months after treatment was lower than that before treatment,the difference was statistically significant(P<0.05).The average number of injection in the study group was lower than that in the total control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Dexamethasone combined with Conbercept is an effective and safe regimen for the treatment of ME secondary to BRVO,which can effectively reduce macular edema,promote visual recovery,and reduce the number of additional injections.